Pregnancy, the postpartum period and prothrombotic defects:\ud
risk of venous thrombosis in the MEGA study by Pomp, E.R. et al.
ORIGINAL ARTICLE
Pregnancy, the postpartum period and prothrombotic defects:
risk of venous thrombosis in the MEGA study
E . R . POMP, * A . M. LENSEL INK , * F . R . ROSENDAAL* and C . J . M . DOGGEN*
*Department of Clinical Epidemiology, Leiden University Medical Center; Einthoven Laboratory for Experimental Vascular Medicine, Leiden
University Medical Center; and Thrombosis and Haemostasis Research Center, Leiden University Medical Center, Leiden, the Netherlands
To cite this article: Pomp ER, Lenselink AM, Rosendaal FR, Doggen CJM. Pregnancy, the postpartum period and prothrombotic defects: risk of
venous thrombosis in the MEGA study. J Thromb Haemost 2008; 6: 632–7.
Summary. Background: Venous thrombosis is one of the
leading causes of maternal morbidity and mortality.
Objective: In the MEGA study, we evaluated pregnancy and
the postpartum period as risk factors for venous thrombosis in
285 patients and 857 control subjects. Patients/methods:
BetweenMarch 1999 and September 2004, consecutive patients
with a first episode of venous thrombosiswere included from six
anticoagulation clinics. Partners of patients and a random digit
dialing group were included as control subjects. Participants
completedaquestionnaireandDNAwascollected. Results: The
riskof venous thrombosiswas 5-fold (OR, 4.6; 95%CI, 2.7–7.8)
increased during pregnancy and 60-fold (OR, 60.1; 95% CI,
26.5–135.9) increased during the first 3 months after delivery
compared with non-pregnant women. A 14-fold increased risk
of deep venous thrombosis of the leg was found compared with
a 6-fold increased risk of pulmonary embolism. The risk was
highest in the third trimester of pregnancy (OR, 8.8; 95% CI,
4.5–17.3) and during the first 6 weeks after delivery (OR, 84.0;
95% CI, 31.7–222.6). The risk of pregnancy-associated venous
thrombosis was 52-fold increased in factor V Leiden carriers
(OR, 52.2; 95%CI, 12.4–219.5) and31-fold increased in carriers
of the prothrombin 20210A mutation (OR, 30.7; 95% CI, 4.6–
203.6) compared with non-pregnant women without the
mutation. Conclusion: We found an increased risk of venous
thrombosis during pregnancy and the postpartum period, with
an especially high risk during the first 6 weeks postpartum. The
risk of pregnancy-associated venous thrombosis was highly
increased in carriers of factor V Leiden or the prothrombin
20210A mutation.
Keywords: case–control study, epidemiology, pregnancy, risk
factors, venous thrombosis.
Introduction
Venous thrombosis is one of the leading causes of maternal
morbidity and mortality [1,2]. In developed countries, about
15% of maternal deaths result from pulmonary embolism [3].
In women of reproductive age, over half of all venous
thrombotic events are related to pregnancy [4].
A large study of pregnancy-associated venous thrombosis is
the Glasgow study, a retrospective study of over 72 000
deliveries [5]. This study reported an incidence of pregnancy-
associated venous thrombosis of 3.24 per 1000 women years,
with an incidence of 2.45 per 1000 women years for deep
venous thrombosis of the leg and an incidence of 0.79 per 1000
women years for pulmonary embolism. For deep venous
thrombosis of the leg the majority of cases (84%) occurred in
the left leg, which is in accordance with the findings of other
studies [6,7]. The mechanism behind this propensity for the left
leg is still under debate [8]. During pregnancy, the risk was
highest during the third trimester [5]. Findings of other studies
addressing risk differences in the three trimesters of pregnancy
are inconsistent. An equal risk distribution during all three
trimesters of pregnancy has been reported but there are also
studies showing the highest risk during the first or second
trimester of pregnancy [6–10]. The incidence of thrombosis was
highest during the first 6 weeks after delivery, both for deep
venous thrombosis of the leg and for pulmonary embolism [5].
A higher risk during the postpartum period compared with
pregnancy is reported by many other studies [10,11].
As women with thrombophilia are at increased risk of
venous thrombosis, a number of studies have been carried
out to study the effect of pregnancy and the postpartum
period in these women [12–17]. The most common inherited
thrombophilias are the factor (F) V Leiden and the
prothrombin 20210A mutation. A meta-analysis of throm-
bophilias in pregnant women has shown the risk to be over
8-fold higher for heterozygous FV Leiden carriers and
almost 7-fold higher for heterozygous prothrombin 20210A
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mutation carriers than in pregnant women without thrombo-
philia [18].
In the Multiple Environmental and Genetic Assessment of
risk factors for venous thrombosis (MEGA study), a large
population-based case–control study, we evaluated pregnancy
and the postpartum period as risk factors for venous throm-
bosis. We were able to identify a sufficient number of patients
in their pregnancy or postpartum period to allow for subgroup
analyses; we evaluated the pregnancy-associated risk of deep
venous thrombosis of the leg and pulmonary embolism
separately and also analyzed the risk of specific time frames
within the pregnant and postpartum period. In addition, the
joint effect of pregnancy with FV Leiden and the prothrombin
20210A mutation was addressed.
Methods
Participants
The MEGA study included consecutive patients with a first
diagnosis of venous thrombosis. Between March 1999 and
September 2004, patients were recruited from six regional
anticoagulation clinics (Amersfoort, Amsterdam, Den Haag,
Leiden, Rotterdam and Utrecht), which monitor the antico-
agulant therapy of all patients within a well-defined geograph-
ical area in the Netherlands. In order to participate, patients
were required to be between the age of 18 and 70. Patients with
severe psychiatric problems or those unable to speak Dutch
were for practical reasons considered ineligible.Within the total
patient group the diagnosis of 97% of deep venous thrombosis
and 79% of pulmonary embolism was objectively confirmed.
Ninety percent of patients used in the final analysis had an
objectively confirmed diagnosis. Seven out of 285 patients
(2.5%) had no objectively confirmed diagnosis and 21 out of
285 patients did not provide permission to obtain their medical
records (7.4%). The tests included compression ultrasonogra-
phy, Doppler ultrasound, impedance plethysmography and
contrast venography for diagnosis of deep venous thrombosis
and perfusion and ventilation lung scanning, spiral computer
tomography and pulmonary angiography for pulmonary
embolism.
Partners of patients were asked to participate as control
subjects and an additional control group was obtained using
the random digit dialing (RDD) method [19]. Only control
subjects with no recent history of venous thrombosis were
included and the same exclusion criteria as for patients were
applied. Details of the MEGA study have been published
previously [20].
Of 6055 eligible patients, 5051 participated (83%). Within
this group, 2737 were women and 2714 provided information
on whether they had been pregnant or not before the
thrombotic event. Of the 5051 participating patients, 3656
had an eligible partner, of whom 2982 participated (82%). An
additional 314 partners were included, of whom the patient was
either excluded for the final analysis, or had deep venous
thrombosis of the arm. Thus a total of 3298 partners were
willing to participate. Within this group 1665 were women, of
whom 1645 provided pregnancy-related information. Out of
4350 eligible RDD control subjects, 3000 were willing to
participate (69%). Information on pregnancy was obtained
from 1710 out of 1719 women in this group. Individuals who
were over 50 years of age, had no partner, used oral
contraceptives or hormone replacement therapy or had malig-
nancy or a partner with malignancy (for patients and partner
controls) were excluded from the analyses, leading to 285
patients and 857 control subjects.
The study was approved by the Medical Ethics Committee
of the Leiden University Medical Center, the Netherlands.
Written informed consent was obtained from all participants.
Data collection
Participants completed a detailed questionnaire on risk factors
for venous thrombosis. Items covered in the questionnaire
included oral contraceptive use, hormone replacement therapy,
pregnancies, malignancies, and civil status. The questionnaire
covered a 1-year period prior to the index date; that is, the date
of diagnosis of the thrombosis for patients and the date of
filling in the questionnaire for partners and the random control
subjects. When participants were not willing to or unable to fill
in the questionnaire, a standardized mini-questionnaire was
taken by telephone, which also included pregnancy-related
questions. Participants were asked if they had been pregnant in
the year before the index date or if they were still pregnant, and
what the (expected) date of delivery was. We defined
postpartum as the period up to 3 months after delivery.
Information on the location of the affected leg in patients with
a deep venous thrombosis of the leg was retrieved from the
questionnaire and discharge letters. Out of 285 patients, 176
had a deep venous thrombosis of the leg (with or without
pulmonary embolism), of whom 173 had information regard-
ing the affected leg.
DNA collection
Three months after discontinuation of anticoagulant therapy
patients and partner controls were invited for an interview and
blood draw. In patients who continued anticoagulant therapy
for over a year after the event, blood was drawn during
anticoagulant therapy. When the participant was unable to
come to the clinic a buccal swab was sent. From June 2002
onwards, blood draws were no longer performed in patients
and their partners and blood draws were replaced by buccal
swabs. Upon completion of the questionnaire, RDD controls
were invited for an interview and blood draw. A detailed
description of blood collection and DNA analysis for the FV
Leiden (G1691A) and the prothrombin mutation (G20210A)
in the MEGA study has been published previously [20].
Within the patient group used for the present analyses, 256
provided a blood sample or buccal swab (90%). In the control
group, 681 blood samples or buccal swabs were obtained
(79%). Factor V Leiden and the prothrombin 20210A
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mutation were successfully determined in all patients and 679
control subjects.
Statistical analysis
As estimates of relative risks, odds ratios (ORs) and 95%
confidence intervals (95% CI) were calculated according to the
method of Woolf. With a multiple logistic regression model we
adjusted for age (categorical, seven classes). Because none of
the control subjects in the analysis were matched to patients
(they were either random population controls or partners of
other (male) patients) all analyses were unmatched, with
unconditional logistic regression. SPSS for Windows version
12.0.1 (SPSS Inc., Chicago, IL, USA) was used for all statistical
analyses.
Results
A group of 285 women aged 18–50 with venous thrombosis
and 857 control subjects in the same age groupwere included in
the analysis, with a mean age of, respectively, 38.3 (5th–95th
percentile, 25.7–49.6) and 39.9 years (5th–95th percentile, 27.0–
49.8). In the patient group 55% (n = 158) were diagnosedwith
a deep venous thrombosis of the leg, 38% (n = 109) with a
pulmonary embolism and 6% (n = 18) with the combined
diagnosis.
Within the patient group, 116 out of 285 women (41%) were
pregnant at the time of thrombosis or had been pregnant
during the 3 months before the thrombosis, compared with 82
out of 857 (9.6%) control subjects at the index date. The risk of
venous thrombosis was 5-fold (OR, 4.6; 95% CI, 2.7–7.8)
increased during pregnancy and 60-fold (OR, 60.1; 95% CI,
26.5–135.9) increased during the first 3 months after delivery
compared with non-pregnant women (Table 1). Odds ratios
were higher in young women than in older women: in women
aged 18–29 the risk of venous thrombosis during pregnancy
was almost 13-fold increased (OR, 12.5; 95% CI, 4.0–39.5),
whereas in women aged 30–50 the risk was 3-fold increased
(OR, 3.3, 95%CI, 1.8–6.1). Postpartum the risk was also more
pronounced in women aged 18–29 (OR, 299.3; 95% CI, 49.4–
1813.1) than in women aged 30–50 (OR, 29.4; 95% CI, 12.1–
71.5) (Table 1).
The risk of venous thrombosis during the first two trimesters
of pregnancy appeared to be only slightly increased, with an
odds ratio of 1.6. However, the risk was increased 9-fold (OR,
8.8; 95% CI, 4.5–17.3) during the third trimester compared
with non-pregnant women. During the first 6 weeks after
delivery the risk was highest (OR, 84.0; 95% CI, 31.7–222.6).
Most cases of venous thrombosis during this period occurred
within the first 4 weeks (95%), with the highest number of cases
in the second week (42%) compared with 18%, 20% and 15%
in the first, third and fourth week. The risk remained increased
up to 3 months postpartum (Table 2).
Overall pregnancy associated risk was most pronounced for
deep vein thrombosis of the leg (OR, 14.3; 95% CI, 8.3–24.5)
and 6-fold increased for pulmonary embolism (OR, 5.8; 95%
CI, 3.3–10.3. During pregnancy, the risk of deep venous
thrombosis of the leg was clearly increased (OR, 7.8; 95% CI,
4.1–15.0), whereas that of pulmonary embolism was at most
weakly increased (OR, 2.3; 95% CI, 1.0–5.2). In the
postpartum period the risk for both was increased, with a
relative risk of 72.6 for deep venous thrombosis of the leg and a
relative risk of 34.4 for pulmonary embolism (Table 3).
The majority of pregnancy-associated deep venous throm-
bosis cases occurred in the left leg. During pregnancy 85% of
women (23 out of 27) had a left-sided deep venous thrombosis,
comparedwith 68% (32 out of 47) of women in the postpartum
period. In women who were not pregnant the right-left
distribution was almost even, with 53% (52 out of 99)
diagnosed with a left-sided deep venous thrombosis.
Table 1 Relative risk of venous thrombosis during pregnancy and post-
partum; overall and by age category
Age group
(years) Status
Patients
(n)
Control
subjects
(n) OR* 95% CI
18–50 Neither 169 775 1 Ref.
Pregnant 36 58 4.6 2.7–7.8
Postpartum 69 10 60.1 26.5–135.9
Overall§ 116 82 9.7 6.4–14.9
18–29 Neither 7 86 1 Ref.
Pregnant 14 18 12.5 4.0–39.5
Postpartum 34 3 299.3 49.4–1813.1
30–50 Neither 162 689 1 Ref.
Pregnant 22 40 3.3 1.8–6.1
Postpartum 35 7 29.4 12.1–71.5
Ref., reference category; OR, odds ratio; 95% CI, 95% confidence
interval.
*Adjusted for age.
Four women who currently were and had previously been pregnant
are included in the pregnant group.
Period up to 3 months after delivery.
§Included the pregnant and postpartum category and an additional 11
cases and 14 control subjects for whom delivery dates were unavail-
able.
Table 2 Relative risk of venous thrombosis by different stages of preg-
nancy and postpartum
Status
Patients,
n (%)
Control
subjects,
n (%) OR* 95% CI
Neither 167 (60.9) 735 (87.2) 1 Ref.
1st and 2nd trimester 8 (2.9) 36 (4.3) 1.6 0.7–3.7
3rd trimester 28 (10.2) 22 (2.6) 8.8 4.5–17.3
1 to 6 weeks
postpartum
66 (24.1) 6 (0.7) 84.0 31.7–222.6
7 weeks to 3rd month
postpartum
3 (1.1) 4 (0.5) 8.9 1.7–48.1
4th month to 1 year
postpartum
2 (0.8) 40 (4.7) 0.3 0.1–1.4
Information on delivery dates was unavailable for 11 cases and 14
controls.
Ref., reference category; OR, odds ratio; 95% CI, 95% confidence
interval.
*Adjusted for age.
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Among non-carriers of FV Leiden, pregnancy and the
postpartum period resulted in a 9-fold increased risk of venous
thrombosis (OR, 8.6; 95%CI, 5.2–14.3). The joint effect of FV
Leiden and pregnancy resulted in a 52-fold increased risk (OR,
52.2; 95% CI, 12.4–219.5), compared with non-carriers who
had not been pregnant (Table 4). The risk of pregnancy-
associated venous thrombosis was 31-fold increased (OR,
30.7; 95% CI, 4.6–203.6) in carriers of the prothrombin
20210A mutation, compared with non-pregnant, non-carriers
(Table 4).
Discussion
In this population-based case–control study we found a 5-fold
increased risk of venous thrombosis during pregnancy and a
60-fold increased risk of venous thrombosis in the postpartum
period. The risk was especially high during the first 6 weeks
after delivery. The risk of both deep venous thrombosis of the
leg and pulmonary embolism was increased during preg-
nancy and the postpartum period. During pregnancy venous
thrombosis occurred far more often in the left than in the right
leg. In carriers of the FV Leiden mutation the risk of
pregnancy-associated venous thrombosis increased markedly
to about 52-fold compared with non-carriers who had not
been pregnant. A somewhat lower increase in risk was found
in prothrombin 20210A carriers, in whom the risk was
31-fold increased, compared with non-carrying, non-pregnant
women.
Our finding of a 5-fold increased risk in women who were
pregnant is in accordance with the results of other studies
[10,11]. The higher relative risks of pregnancy in younger
women compared with older women were in contrast to
previous follow-up studies. However, one should bear in mind
the difference between relative and absolute risks. As throm-
bosis is age dependent, these two will never both be constant
over age, and a similar absolute increase will lead to much
higher relative risks in young than in older women. Hence, one
cannot conclude from our data that the influence is lower in
older than in younger women and the reverse is probably true,
also based on these data.
While previous reports were conflicting about the risk per
trimester of pregnancy [6–10], we found the highest risk during
the third trimester. These findings should be interpreted with
some caution, because the higher risk during the third trimester
might reflect a relatively high number of misdiagnoses in this
trimester due to compression issues by the gravid uterus that
lead to symptoms similar to venous thrombosis [8]. However,
this is not very likely in our study, because 97%of patients with
deep venous thrombosis were objectively diagnosed. A more
important consideration is the inclusion of patients through
anticoagulation clinics. Some women with venous thrombosis
during pregnancy are initially treated without involvement of
the anticoagulation clinic and receive low molecular weight
heparin (LMWH). Women who had their venous thrombosis
during the first or second trimester are more likely to be treated
with LMWH only than women with a venous thrombosis
during the third trimester, who are referred to the anticoag-
ulation clinic for additional treatment after child delivery. This
might have led to an underestimate of the risk of thrombosis
during early stages of pregnancy, thus no firm conclusion can
be drawn about lower risks in the first two trimesters compared
with the third trimester.
The risk of venous thrombosis during the first 6 weeks after
delivery was very high compared with the overall pregnancy-
associated risk. Our finding of a 84-fold higher risk during this
period is within the range of findings from themajority of other
studies, that reported a 2- to 15-fold increased risk during the
Table 3 Risk of deep venous thrombosis, pulmonary embolism and the
combined diagnosis by pregnancy status
Patients
(n)
Control
subjects (n) OR* 95% CI
DVT
Neither 83 775 1 Ref.
Pregnant 27 58 7.8 4.1–15.0
Postpartum 42 10 72.6 30.1–175.4
Overall 75 82 14.3 8.3–24.5
PE
Neither 73 775 1 Ref.
Pregnant 9 58 2.3 1.0–5.2
Postpartum 22 10 34.4 13.3–88.5
Overall 36 82 5.8 3.3–10.3
DVT+PE
Neither 13 775 1 Ref.
Pregnant 0 58 – –
Postpartum 5 10 46.4 10.0–214.7
Overall§ 5 82 5.5 1.4–21.1
DVT, deep venous thrombosis of the leg; PE, pulmonary embolism;
Ref., reference category; OR, odds ratio; 95% CI, 95% confidence
interval.
*Adjusted for age.
Included the pregnant and postpartum category and an additional 6
cases and 14 control subjects for whom delivery dates were unavail-
able.
Included the pregnant and postpartum category and an additional 5
cases and 14 control subjects for whom delivery dates were unavail-
able.
§Included the pregnant and postpartum category and an additional 14
control subjects for whom delivery dates were unavailable.
Table 4 The joint effect of pregnancy status and the factor V Leiden
mutation (FVL) or the prothrombin 20210A (FII) mutation
Pregnant or
postpartum FVL
Patients
(n)
Control
subjects (n) OR* 95% CI
) ) 144 580 1 Ref.
+ ) 81 56 8.6 5.2–14.3
) + 12 40 1.3 0.6–2.5
+ + 19 3 52.2 12.4–219.5
FII
) ) 141 605 1 Ref.
+ ) 94 57 10.1 6.2–16.4
) + 15 15 4.4 2.1–9.4
+ + 6 2 30.7 4.6–203.6
Ref., reference category; OR, odds ratio; 95% CI, 95% confidence
interval.
*Adjusted for age.
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first 6 weeks after delivery compared with pregnancy [7,14,21].
The Glasgow study found 2.51 cases of venous thrombosis per
1000 person years in the first 6 weeks after delivery [5]. When
we contrast this figure with the baseline risk of venous
thrombosis of 0.08 per 1000 in these young women [22], these
data point to a relative risk of 31 during this period. A case–
control study in which control subjects were subject to the same
referral and diagnostic procedures as patients found, however,
less difference in the thrombotic risks during the first month
after delivery and pregnancy [23]. A high risk of venous
thrombosis during the first weeks after delivery may be
explained by coagulation changes due to operative delivery,
postnatal infections or immobility [24].
For a correct calculation of relative risks during different
stages of pregnancy and the postpartum period it is important
that the proportion of control subjects in each time frame is a
good reflection of the source population. To verify this, we
calculated the expected number of controls in each period,
using data from the general population [25]. The percentage of
pregnant or postpartumwomenwas higher in the random digit
dialing control group (12.3%) than in the partner control
group (3.8%). In the overall control group the incidence of
pregnant or postpartum women (8.1%) was similar to the
general population (8.8%). During pregnancy the proportion
of controls was similar to what we would expect to find (6.9%
compared with an expected 6.6%). In the first 3 months
postpartum we observed a lower proportion of controls (1.2%
compared with an expected 2.2%), possibly due to a reduced
motivation to participate in our study after child delivery. In
the period from 4 months up to 1 year postpartum the
proportion of controls was still somewhat reduced (4.7%
compared with an expected 6.6%). These lower proportions
have probably resulted in a slight overestimation of relative
risks in the postpartum period.
Furthermore, the time needed for control subjects to return
the questionnaire could have influenced the percentage of
pregnant controls assigned to each period. As controls returned
the questionnaire more quickly than patients and 61% of the
controls had replied within a week (86%within amonth) this is
unlikely to have affected results.
Not much is known about the relative risks of the separate
diagnoses of deep venous thrombosis of the leg and pulmonary
embolism, during and after pregnancy. An American cohort
study reported an increased risk of deep venous thrombosis
and pulmonary embolism during pregnancy. Postpartum the
risks were further increased, with a 4-fold higher risk of deep
venous thrombosis and a 15-fold increased risk of pulmonary
embolism compared with the pregnant period [10]. Also a
Danish cohort study reported an increased risk of both deep
venous thrombosis and pulmonary embolism during preg-
nancy and the first 6 weeks after delivery, with again a higher
risk of pulmonary embolism during the postpartum period
compared with the pregnant period [26]. We found increased
risks of deep venous thrombosis of the leg and pulmonary
embolism postpartum, while during pregnancy the risk of
pulmonary embolism was only slightly increased.
When analyzing the combined effect of pregnancy and the
postpartum period with the FV Leiden mutation or the
prothrombin 20210Amutation, we found substantial increased
risks for the combination of these risk factors. A meta-analysis
of thrombophilias in pregnancy has found an 8-fold higher risk
for heterozygous FV Leiden carriers and an almost 7-fold
higher risk for heterozygous prothrombin 20210A mutation
carriers than pregnant women without thrombophilia [18].
Performing our analysis within pregnant women only, we
found a 5-fold increased risk for FV Leiden carriers and a 2-
fold increased risk for prothrombin 20210A carriers.
In these young women, we found a low relative risk of 1.3 in
carriers of FV Leiden who had not been pregnant, which is
lower than the overall risk of venous thrombosis due to FV
Leiden (3- or more fold increased) [27]. To investigate if the low
risk was due to a too large proportion of non-pregnant FV
Leiden carriers among control subjects, we calculated the
relative risk of venous thrombosis that one would expect in
these control subjects using data from the general Dutch
population as control situation. Using general data on live
birth, stillbirth and use of oral contraceptives we calculated that
8.8%of these young womenwere expected to be pregnant or in
the postpartum period [25]. Together with an incidence of 5%
for FV Leiden [28], the calculated relative risk would be 1.5 in
carriers of FVLeiden compared with non-carriers who had not
been pregnant; a similar relative risk as our finding (with 144
patients of the reference category and the 12 non-pregnant
patients with FV Leiden the following calculation was
performed: 144 * (5*(1)0.088)/95 * (1)0.088)) = 7.76, 12/
7.76 = 1.5).
We performed several subgroup analyses with relatively
small numbers of patients and control subjects. Several
confidence intervals were wide, but results were in accordance
with previous studies and the lower boundaries of many
confidence intervals were above 2.1, with odds ratios of 4.4 or
higher, indicating that the true effects were likely to be
substantial.
A limitation of our study was the absence of data on the
mode of delivery. It would have been interesting to investigate
if we could replicate or refute previous findings that reported an
increased risk of venous thrombosis from vaginal delivery to
elective Caesarean section to emergency Caesarean section [2].
In conclusion, we found an increased risk of venous
thrombosis during both pregnancy and the postpartum period,
with an especially high risk during the first 6 weeks after
delivery. Women with either FV Leiden or prothrombin
20210A thrombophilia had a substantially increased risk of
pregnancy-associated venous thrombosis compared with
women without these mutations.
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